Fabrazyme IV 35mg, containing Agalsidase beta (genetically recombinant), is manufactured by Sanofi. This injectable drug, with YJ code 3959409D2025 and standard 35mg x 1 bottle, is an enzyme replacement therapy indicated for the treatment of Fabry disease.
Fabrazyme IV 35mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →